Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo

Fig. 2

Anti-CAIX IgG1 mAbs modulate the motility of CAIX+ RCC. (a) Cell migration assayed by transwell migration, using CAIX+ SKRC-52 cells and treatment with anti-CAIX mAbs (2.5 μg/ml), non-specific control antibody (2.5 μg/ml), or acetazolamide (AZ, 100 μM). Migration was measured after 24 h, in response to HGF in the lower chamber. (b) Wound healing assay of CAIX+ RCC cells in the presence of anti-CAIX mAbs (10 μg/ml), non-specific control antibody (10 μg/ml), or acetazolamide (AZ, 100 μM). Confluent monolayer of SKRC-52 cells were wounded, and after 24 h healing calculated as the area not containing cells as measured by microscopy. (c) Cellular proliferation of CAIX+ RCC cells, measured in conditions as above, through 4 days post-treatment. All data represent mean values ± S.D. of three independent experiments, each experiment performed in triplicate. * represents p value of student t-test < 0.05, compared to control antibody

Back to article page